Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19.

Literature DB >> 35076671

Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19.

Abstract

Entities: Chemical

Year: 2022 PMID： 35076671 DOI： 10.1001/jama.2021.24931

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

Keyword Cloud
Cited

× No keyword cloud information.

28 in total

Review 1. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19.

Authors: Gaetano Alfano; Niccolò Morisi; Monica Frisina; Annachiara Ferrari; Francesco Fontana; Roberto Tonelli; Erica Franceschini; Marianna Meschiari; Gabriele Donati; Giovanni Guaraldi
Journal: Infez Med Date: 2022-03-01

2. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Authors: Thomas Marjot; Christiane S Eberhardt; Tobias Boettler; Luca S Belli; Marina Berenguer; Maria Buti; Rajiv Jalan; Mario U Mondelli; Richard Moreau; Daniel Shouval; Thomas Berg; Markus Cornberg
Journal: J Hepatol Date: 2022-07-20 Impact factor: 30.083

Review 3. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.

Authors: Caroline Hirsch; Yun Soo Park; Vanessa Piechotta; Khai Li Chai; Lise J Estcourt; Ina Monsef; Susanne Salomon; Erica M Wood; Cynthia So-Osman; Zoe McQuilten; Christoph D Spinner; Jakob J Malin; Miriam Stegemann; Nicole Skoetz; Nina Kreuzberger
Journal: Cochrane Database Syst Rev Date: 2022-06-17

4. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.

Authors: Adrian M Shields; Sian E Faustini; Harriet J Hill; Saly Al-Taei; Chloe Tanner; Fiona Ashford; Sarita Workman; Fernando Moreira; Nisha Verma; Hollie Wagg; Gail Heritage; Naomi Campton; Zania Stamataki; Mark T Drayson; Paul Klenerman; James E D Thaventhiran; Shuayb Elkhalifa; Sarah Goddard; Sarah Johnston; Aarnoud Huissoon; Claire Bethune; Suzanne Elcombe; David M Lowe; Smita Y Patel; Sinisa Savic; Alex G Richter; Siobhan O Burns
Journal: Front Immunol Date: 2022-06-02 Impact factor: 8.786

Review 5. Immune treatment in COVID-19.

Authors: R Menéndez; P González; A Latorre; R Méndez
Journal: Rev Esp Quimioter Date: 2022-04-22 Impact factor: 2.515

10. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.

Authors: Katarina Nyström; Maria Hjorth; Ramona Fust; Åsa Nilsdotter-Augustinsson; Marie Larsson; Katarina Niward; Sofia Nyström
Journal: BMC Infect Dis Date: 2022-04-11 Impact factor: 3.090

Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19.

Review 1. Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19.

2. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper.

Review 3. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.

4. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.

Review 5. Immune treatment in COVID-19.

Review 6. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Review 7. Antibodies to combat viral infections: development strategies and progress.

8. Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis.

Review 9. Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next.

10. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.